Amgen Inc. closed 14.87% below its 52-week high of $346.85, which the company reached on July 25th.

A court battle between two of the nation’s largest biotechs is testing the legal limits of how far drugmakers can go in using ...

Amgen Inc. closed 13.40% below its 52-week high of $346.85, which the company achieved on July 25th.

Amgen (AMGN) closed at $295.18 in the latest trading session, marking a -1.73% move from the prior day. The stock's performance was behind the S&P 500's daily loss of 0.33%. Elsewhere, the Dow saw a ...

Amgen has transitioned into a mature, cash-generating pharma-biotech hybrid. Click here to find out why AMGN stock is a Buy.

A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...

From Amgen's classic double-bottom base in February 1990 until it ultimately topped in the summer of 2000, it increased more ...

The phase 3 FORTITUDE-101 trial, conducted with the support of Zai Lab, has been evaluating bemarituzumab plus mFOLFOX6 ...

The idea for Amgen’s first foray into documentary film started with two numbers, according to Nerissa Gomes, general manager ...

Amgen said on Monday its experimental therapy helped patients with advanced gastric cancer live longer when combined with ...

Eric Groen will serve as legal chief, compliance chief and head of business development for Genelux Corp., which is led by a ...

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...